✦ LIBER ✦

PCN110 Economic Evaluation of Gefitinib for First-Line Treatment of EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer Patients in Greece

✍ Scribed by Fragoulakis, V.; Pallis, A.; Kourlaba, G.; Georgoulias, V.; Maniadakis, N.

Book ID: 122310799
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 61 KB
Volume: 14
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.08.1211

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-Line Gefitinib in Patients With Ad

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

✍ Sequist, L. V.; Martins, R. G.; Spigel, D.; Grunberg, S. M.; Spira, A.; Janne, P 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 228 KB

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMEN

PCN7 COMPARATIVE EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER

✍ B. Schwander; J. de Castro Carpeño; D.F. Heigener; E. Wright; H.G. Bischoff; S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Influence of first-line chemotherapy and

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer

✍ Wu, Jenn-Yu; Yu, Chong-Jen; Shih, Jin-Yuan; Yang, Chih-Hsin; Yang, Pan-Chyr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 374 KB

26 Audit of gefitinib for the first-line

26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation

✍ Douglas, R.; Campbell, L.; McAleese, J.; Scullin, P. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Gene-guided Gefitinib switch maintenance

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

✍ Jun Zhu, Te Li, Xiaohui Wang, Ming Ye, Jian Cai, Yuejuan Xu, Bin Wu 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 278 KB

NICE guidance on erlotinib for first-lin

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer

✍ Bernice Dillon; Bhash Naidoo; Helen Knight; Peter Clark 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 44 KB